The updated 2024-2025 mRNA COVID vaccine from Moderna does not appear to carry the same risk for myocarditis in young adults that the first mRNA COVID vaccines did, suggested research presented at the ...

Add Yahoo as a preferred source to see more of our stories on Google. A nurse draws up doses of the Moderna COVID-19 for a vaccination clinic in St. Helena in 2021. Moderna is offering a new, low-dose ...

Starting this autumn, adults aged 50 and older across the European Union may be able to roll up their sleeve just once and ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting marketing authorization for Moderna’s new RNA-based vaccine, mNexspike, for preventing ...

mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA / ACCESS Newswire / February 17, 2026 / ...

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...

You may have seen ads for a new, lower-dose Moderna COVID vaccine marketed to "the senior class" - adults 65 and older. The new vaccine, which goes by mRNA-1283 or mNexspike, was approved by the U.S.